Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.

Sykes DA, Bradley ME, Riddy DM, Willard E, Reilly J, Miah A, Bauer C, Watson SJ, Sandham DA, Dubois G, Charlton SJ.

Mol Pharmacol. 2016 May;89(5):593-605. doi: 10.1124/mol.115.101832. Epub 2016 Feb 25.

PMID:
26916831
2.

Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor.

Rosethorne EM, Bradley ME, Gherbi K, Sykes DA, Sattikar A, Wright JD, Renard E, Trifilieff A, Fairhurst RA, Charlton SJ.

Mol Pharmacol. 2016 Apr;89(4):467-75. doi: 10.1124/mol.115.101253. Epub 2016 Jan 15.

PMID:
26772612
3.

Functional desensitization of the β 2 adrenoceptor is not dependent on agonist efficacy.

Rosethorne EM, Bradley ME, Kent TC, Charlton SJ.

Pharmacol Res Perspect. 2015 Feb;3(1):e00101. doi: 10.1002/prp2.101. Epub 2015 Jan 5.

4.

Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action.

Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, De Taeye S, Van den Heede K, Roobrouck A, Grot E, Kent TC, Laeremans T, Steffensen S, Van Heeke G, Brown Z, Charlton SJ, Cromie KD.

Mol Pharmacol. 2015 Feb;87(2):251-62. doi: 10.1124/mol.114.094821. Epub 2014 Dec 2.

PMID:
25468882
5.

Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization.

Sykes DA, Riddy DM, Stamp C, Bradley ME, McGuiness N, Sattikar A, Guerini D, Rodrigues I, Glaenzel A, Dowling MR, Mullershausen F, Charlton SJ.

Br J Pharmacol. 2014 Nov;171(21):4797-807. doi: 10.1111/bph.12620.

6.

An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.

Beattie D, Beer D, Bradley ME, Bruce I, Charlton SJ, Cuenoud BM, Fairhurst RA, Farr D, Fozard JR, Janus D, Rosethorne EM, Sandham DA, Sykes DA, Trifilieff A, Turner KL, Wissler E.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6280-5. doi: 10.1016/j.bmcl.2012.07.096. Epub 2012 Aug 4.

PMID:
22932315
7.

The in vitro metabolism of sphingosine-1-phosphate: identification; inhibition and pharmacological implications.

Bradley ME, McGuinness N, Williams G, Charlton SJ, Dowling MR.

Eur J Pharmacol. 2011 Dec 15;672(1-3):56-61. doi: 10.1016/j.ejphar.2011.09.178. Epub 2011 Sep 29.

PMID:
21970805
8.

A common intracellular allosteric binding site for antagonists of the CXCR2 receptor.

Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, Bradley ME.

Br J Pharmacol. 2010 Apr;159(7):1429-39. doi: 10.1111/j.1476-5381.2009.00623.x. Epub 2010 Mar 3.

9.

Sequestration of essential proteins causes prion associated toxicity in yeast.

Vishveshwara N, Bradley ME, Liebman SW.

Mol Microbiol. 2009 Sep;73(6):1101-14. doi: 10.1111/j.1365-2958.2009.06836.x. Epub 2009 Aug 11.

10.

SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.

Bradley ME, Bond ME, Manini J, Brown Z, Charlton SJ.

Br J Pharmacol. 2009 Sep;158(1):328-38. doi: 10.1111/j.1476-5381.2009.00182.x. Epub 2009 Apr 24. Erratum in: Br J Pharmacol. 2009 Oct;158(3):931.

11.

Sulfate activation enzymes: phylogeny and association with pyrophosphatase.

Bradley ME, Rest JS, Li WH, Schwartz NB.

J Mol Evol. 2009 Jan;68(1):1-13. doi: 10.1007/s00239-008-9181-6. Epub 2008 Dec 6.

PMID:
19067028
12.

The role of voltage-gated potassium channels in the regulation of mouse uterine contractility.

Smith RC, McClure MC, Smith MA, Abel PW, Bradley ME.

Reprod Biol Endocrinol. 2007 Nov 2;5:41.

13.

Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting.

Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH.

Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):271-6.

PMID:
17333081
16.
17.

Destabilizing interactions among [PSI(+)] and [PIN(+)] yeast prion variants.

Bradley ME, Liebman SW.

Genetics. 2003 Dec;165(4):1675-85. Erratum in: Genetics. 2011 Aug;188(4):1023.

18.

Guanidine reduces stop codon read-through caused by missense mutations in SUP35 or SUP45.

Bradley ME, Bagriantsev S, Vishveshwara N, Liebman SW.

Yeast. 2003 May;20(7):625-32.

19.

Tonic inhibitory role for cAMP in alpha(1a)-adrenergic receptor coupling to extracellular signal-regulated kinases 1/2.

Jiao X, Gonzalez-Cabrera PJ, Xiao L, Bradley ME, Abel PW, Jeffries WB.

J Pharmacol Exp Ther. 2002 Oct;303(1):247-56.

PMID:
12235258
20.

Interactions among prions and prion "strains" in yeast.

Bradley ME, Edskes HK, Hong JY, Wickner RB, Liebman SW.

Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16392-9. Epub 2002 Jul 30.

21.

Purine nucleoside-dependent inhibition of cellular proliferation in 1321N1 human astrocytoma cells.

Bradley KK, Bradley ME.

J Pharmacol Exp Ther. 2001 Nov;299(2):748-52.

PMID:
11602690
22.

Prions affect the appearance of other prions: the story of [PIN(+)].

Derkatch IL, Bradley ME, Hong JY, Liebman SW.

Cell. 2001 Jul 27;106(2):171-82.

23.

Molecular and pharmacological characterization of muscarinic receptor subtypes in a rat parotid gland cell line: comparison with native parotid gland.

Bockman CS, Bradley ME, Dang HK, Zeng W, Scofield MA, Dowd FJ.

J Pharmacol Exp Ther. 2001 May;297(2):718-26.

PMID:
11303063
24.

ATP stimulated cyclic AMP formation in bovine chromaffin cells is enhanced by neuropeptide Y.

Zhang P, Zheng J, Bradley ME, Hexum TD.

Peptides. 2001 Mar;22(3):439-44.

PMID:
11287099
25.

Dependence and independence of [PSI(+)] and [PIN(+)]: a two-prion system in yeast?

Derkatch IL, Bradley ME, Masse SV, Zadorsky SP, Polozkov GV, Inge-Vechtomov SG, Liebman SW.

EMBO J. 2000 May 2;19(9):1942-52.

26.

Molecular diversity of K(V) alpha- and beta-subunit expression in canine gastrointestinal smooth muscles.

Epperson A, Bonner HP, Ward SM, Hatton WJ, Bradley KK, Bradley ME, Trimmer JS, Horowitz B.

Am J Physiol. 1999 Jul;277(1):G127-36. doi: 10.1152/ajpgi.1999.277.1.G127.

PMID:
10409159
27.
28.

Chemotactic, mitogenic, and angiogenic actions of UTP on vascular endothelial cells.

Satterwhite CM, Farrelly AM, Bradley ME.

Am J Physiol. 1999 Mar;276(3):H1091-7. doi: 10.1152/ajpheart.1999.276.3.H1091.

PMID:
10070096
29.

Nitric oxide relaxes human myometrium by a cGMP-independent mechanism.

Bradley KK, Buxton IL, Barber JE, McGaw T, Bradley ME.

Am J Physiol. 1998 Dec;275(6):C1668-73. doi: 10.1152/ajpcell.1998.275.6.C1668.

PMID:
9843729
30.

Nitric oxide regulation of monkey myometrial contractility.

Kuenzli KA, Buxton IL, Bradley ME.

Br J Pharmacol. 1998 May;124(1):63-8.

31.
32.

Surveillance of cryptococcosis in Alabama, 1992-1994.

Thomas CJ, Lee JY, Conn LA, Bradley ME, Gillespie RW, Dill SR, Pinner RW, Pappas PG.

Ann Epidemiol. 1998 May;8(4):212-6.

PMID:
9590599
33.
34.
35.
36.

Genetic and environmental factors affecting the de novo appearance of the [PSI+] prion in Saccharomyces cerevisiae.

Derkatch IL, Bradley ME, Zhou P, Chernoff YO, Liebman SW.

Genetics. 1997 Oct;147(2):507-19.

37.

Yeast two-hybrid cloning of a novel zinc finger protein that interacts with the multifunctional transcription factor YY1.

Kalenik JL, Chen D, Bradley ME, Chen SJ, Lee TC.

Nucleic Acids Res. 1997 Feb 15;25(4):843-9.

38.

Cyclic GMP-independent effects of nitric oxide on guinea-pig uterine contractility.

Kuenzli KA, Bradley ME, Buxton IL.

Br J Pharmacol. 1996 Oct;119(4):737-43.

39.

Analysis of events associated with serum deprivation-induced apoptosis in C3H/Sol8 muscle satellite cells.

Mampuru LJ, Chen SJ, Kalenik JL, Bradley ME, Lee TC.

Exp Cell Res. 1996 Aug 1;226(2):372-80.

PMID:
8806441
40.

Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.

Bradley ME, Foote EF, Lee EN, Merkle L.

Pharmacotherapy. 1996 Jul-Aug;16(4):680-3. Review.

PMID:
8840376
41.

Evidence for a discrete UTP receptor in cardiac endothelial cells.

Yang S, Buxton IL, Probert CB, Talbot JN, Bradley ME.

Br J Pharmacol. 1996 Apr;117(7):1572-8.

42.

Inositolpolyphosphate binding sites and their likely role in calcium regulation in smooth muscle.

Zhang L, Bradley ME, Buxton IL.

Int J Biochem Cell Biol. 1995 Dec;27(12):1231-48. Review. No abstract available.

PMID:
8581820
43.

Isolation and identification of plasma membrane populations.

Bradley ME, Lambert RW, Mircheff AK.

Methods Enzymol. 1994;228:432-48. No abstract available.

PMID:
8047013
44.

Surface and intracellular pools of Na,K-ATPase catalytic and immuno-activities in rat exorbital lacrimal gland.

Bradley ME, Azuma KK, McDonough AA, Mircheff AK, Wood RL.

Exp Eye Res. 1993 Oct;57(4):403-13.

PMID:
8282026
45.

Inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate binding sites in smooth muscle.

Zhang L, Bradley ME, Khoyi M, Westfall DP, Buxton IL.

Br J Pharmacol. 1993 Aug;109(4):905-12.

46.

Adenosine-stimulated contraction in nonpregnant guinea pig myometrium does not involve cyclooxygenase.

Bradley ME, Kuenzli KA, Buxton IL.

J Pharmacol Exp Ther. 1993 Mar;264(3):1033-9.

PMID:
8450447
47.

Involvement of cyclic GMP in non-adrenergic, non-cholinergic inhibitory neurotransmission in dog proximal colon.

Ward SM, Dalziel HH, Bradley ME, Buxton IL, Keef K, Westfall DP, Sanders KM.

Br J Pharmacol. 1992 Dec;107(4):1075-82.

48.

Isolation and subcellular fractionation analysis of acini from rabbit lacrimal glands.

Bradley ME, Lambert RW, Lambert RW, Lee LM, Mircheff AK.

Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2951-65.

PMID:
1326495
49.

Comparison of methods for measuring free thyroxin in nonthyroidal illness.

Wong TK, Pekary AE, Hoo GS, Bradley ME, Hershman JM.

Clin Chem. 1992 May;38(5):720-4.

50.

Action of alpha 2A-adrenergic receptors in circular smooth muscle of canine proximal colon.

Zhang L, Keef KD, Bradley ME, Buxton IL.

Am J Physiol. 1992 Mar;262(3 Pt 1):G517-24.

PMID:
1312795

Supplemental Content

Loading ...
Support Center